Skip to main content

Articles

FDA Approvals
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Read More
FDA Approvals
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Read More
Perspectives
The Continuation of Care
Read More
Introduction
Health Economics in Oncology: A Necessary Tool for Value-Based Patient Care
Read More
Practice Management
Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer
Stakeholder Perspective
Comparing Cost and Utilization of 2 Therapies for Metastatic Castration-Resistant Prostate Cancer
Read More
Practice Management
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework
Stakeholder Perspective
The Rationale for Comparing the Costs of Competing Treatment Options in Oncology
Read More
Practice Management
Oncology Innovation and Challenging Choices: Balancing Value and Funding Priorities in Light of an Abundance of New Treatment Options
Read More
FDA Approvals
The 2015 Oncology Drug Pipeline: Innovation Drives the Race to Cure Cancer
Read More
Perspectives
Did the “HEN” Lay a Rotten Egg?
Read More
Practice Management
Breaking the Bank: Three Financing Models for Addressing the Drug Innovation Cost Crisis
Stakeholder Perspective
Financing Drug Innovation: Cost versus Cure
Read More
Page 132 of 245
Results 1311 - 1320 of 2441